Skip to main content
SpringerLink
Log in

Is body composition an important variable in the pharmacokinetics of anticancer drugs?

A review and suggestions for further research

  • Review
  • Pharmacokinetics, Anticancer Drugs
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Abernethy DR, Greenblatt DJ (1986) Drug disposition in obese humans: an update. Clin Pharm 11:199–213

    Google Scholar 

  2. Abernethy DR, Schwartz JB, Todd EL, Mitchell JR (1985) Verapamil dynamics and disposition in obese hypertensives. Fed Proc 44: 1128

    Google Scholar 

  3. Anonymous (1959) New weight standards for men and women. Stat Bull Metropol Life Ins Co 40:1–4

    Google Scholar 

  4. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet I:307–310

    Google Scholar 

  5. Calvert AH, Newell DR, Gumbrell LA (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756

    Google Scholar 

  6. Chabner BA (1991) Clinical strategies for cancer treatment: the role of drugs. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: Principles and practice, ch 1. Lippincott, Philadelphia, pp 1–15

    Google Scholar 

  7. Cheymol G (1988) Drug pharmacokinetics in the obese. Fundam Clin Pharmacol 2: 239–256

    Google Scholar 

  8. Clarys JP, Martin AD, Drinkwater DT (1984) Gross tissue weights in the human body by cadaver dissection. Hum Biol 56:459–473

    Google Scholar 

  9. Cohn SH, Ellis KJ, Vartsky D, Sawitsky A, Gartenhaus W, Yasamura S, Vaswaric AN (1981) Comparison of methods of estimating body fat in normal subjects and cancer patients. Am J Clin Nutr 34: 2839–2847

    Google Scholar 

  10. Coward WA, Parkinson SA, Murgatroyd PR (1988) Body composition measurements for nutrition research. Nutr Res Rev 1:115–124

    Google Scholar 

  11. Deurenberg PK, Van der Kooy P, Evers P, Hulshof T (1990) Assessment of body composition by bioelectrical impedance in a population aged >60 years. Am J Clin Nutr 51: 3–6

    Google Scholar 

  12. D'Incalci MD, Bulis G, Mangioni C, Morosa L, Gurattini S (1978) Variable absorption of hexamethylmelamine in man. Cancer Treat Rep 62: 2117

    Google Scholar 

  13. D'Incalci M, Beggiolin G, Sessa G, Margionis C (1981) Influence of ascites on the pharmacokinetics of hexamethylmelamine and N-demethylated metabolites in ovarian cancer patients. Eur J Cancer Clin Oncol 17: 1331–1335

    Google Scholar 

  14. Dorsey JL, Smith JT (1981) Comparison of hepatic cytochrome P-450 levels of obese and non-obese mice. Nutr Rep Int 24: 777–781

    Google Scholar 

  15. Durnin JVGA (1989) Anthropometric methods of assessing nutritional status. In: Horwitz A, McFadyen DN, Steen B, Munro HN (eds) Nutrition in the elderly, ch 2. Oxford University Press, Oxford, pp 15–32

    Google Scholar 

  16. Durnin JVGA, Womersley J (1974) Body fat assessed from total body density and its estimation from skinfold thickness measurements on 481 men and women aged 16 to 72 years. Br J Nutr 32: 77–97

    Google Scholar 

  17. Fomon SJ, Haschke F, Ziegler EE, Nelson SE (1982) Body composition of reference children from birth to age 10 years. Am J Clin Nutr 35: 1169–1175

    Google Scholar 

  18. Fleming RA, Eldridge RM, Johnson CE, Stewart CF (1991) Disposition of high-dose methotrexate in an obese cancer patient. Cancer 68: 1247–1250

    Google Scholar 

  19. Friedl KE, Deluca JP, Marchietelli LJ, Vogel JA (1992) Reliability of body fat estimations from a four compartment model by using density, body water, and bone mineral measurements. Am J Clin Nutr 55: 764–770

    Google Scholar 

  20. Fuller NJ, Jebb SA, Laskey MA, Coward WA, Elia M (1992) A four component model for the assessment of body composition in humans. Clin Sci 82: 687–693

    Google Scholar 

  21. Garrow JS (1983) Indices of adiposity. Nutr Abstr Rev 53: 697–708

    Google Scholar 

  22. Gianni L, McVie JG, Workman P (1993) The relevance of pharmacology in clinical oncology practice. Ann Oncol 4: 463–469

    Google Scholar 

  23. Gibson RS (1990) Priciples of nutritional assessment. Oxford University Press, Oxford

    Google Scholar 

  24. Grochow LB, Baraldi C, Noe D (1990) Is dose normalisation to weight or body surface area useful in adults? J Natl Cancer Inst 82: 323–324

    Google Scholar 

  25. Haschke F (1983) Body composition of adolescent males. Acta Paediatr Scand [Suppl] 307: 1–23

    Google Scholar 

  26. Hayder S, Lafolie P, Bjork O, Peterson C (1989) 6-Mercaptopurine plasma levels in children with acute lymphoblatic leukaemia: relation to relapse risk and myelotoxicity. Ther Drug Monit 11: 617–622

    Google Scholar 

  27. Hewitt MJ, Going SB, Williams DP, Lohman TG (1993) Hydration of the fat-free body mass in children and aduts: implications for body composition assessment. Am J Physiol 265: E88-E95

    Google Scholar 

  28. Kobayashi K, Ratain MJ (1993) Individualising dosing in cancer chemotherapy. Semin Oncol 20: 30–42

    Google Scholar 

  29. Lennard L, Lilleyman JS, Van Loan J, et al (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225–228

    Google Scholar 

  30. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM (1989) Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25: 139–142

    Google Scholar 

  31. Lukaski HC (1987) Methods for the assessment of human body composition: traditional and new. Am J Clin Nutr 46: 537–546

    Google Scholar 

  32. Milsap RL, Plaisance KI, Jusko WJ (1984) Prednisolone disposition in obese men. Clin Pharmacol Ther 36: 824–831

    Google Scholar 

  33. McLean KP, Skinner JS (1992) Validity of Futrex-5000 for body composition determination. Med Sci Sports Exerc 24: 253–258

    Google Scholar 

  34. McNeill G, Fowler PA, Maughan RJ, McGaw BA, Fuller MF, Gvozdanovic D, Gvozdanovic S (1991) Body fat in lean and overweight women estimated by six methods. Br J Nutr 65: 95–103

    Google Scholar 

  35. National Center for Health Statistics (1976) NCHS growth charts, monthly vital statistics report (3 HRA 76-1120). Health Resources Administration, Rockville, Maryland

    Google Scholar 

  36. Newell DR (1989) Pharmacokinetic determinants of the activity and toxicity of anti-tumour agents. Cancer Surv 8: 557–603

    Google Scholar 

  37. Office of Population, Censuses and Surveys, UK (1990) The dietary and nutritional survey of British adults. Office of Population, Censuses and Surveys, London

    Google Scholar 

  38. Powis G (1983) Effects of disease states on pharmacokinetics of anticancer drugs. In: Ames MM, Powis G, Kovach JS (eds) Pharmacokinetics of anticancer agents in humans. Elsevier, Amsterdam, pp 363–397

    Google Scholar 

  39. Powis G, Reece P, Ahmann DL, Ingle JN (1987) Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20: 219–222

    Google Scholar 

  40. Ratain MJ, Mick R, Berezin F, et al (1991) Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 50: 573–579

    Google Scholar 

  41. Ratain MJ, Mick R, Schilsky RL, Vogelzong NJ, Berezin F (1991) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9: 1480–1486

    Google Scholar 

  42. Reilly JJ, Fedak MA (1990) Measurement of the body composition of living grey seals by hydrogen isotope dilution. J Appl Physiol 69: 885–891

    Google Scholar 

  43. Reilly JJ, Workman P (1993) Normalisation of anticancer drug dosage using body weight and surface area: is it worthwhile? Cancer Chemother Pharmacol 32: 411–418

    Google Scholar 

  44. Reilly JJ, Odame I, McColl J, McAllister P, Gibson B, Wharton BA (1994) Does weight for height have prognostic significance in children with acute lymphoblastic leukaemia? Am J Pediatr Hematol Oncol (in press)

  45. Reilly JJ, Murray L, Wilson J, Durnin JVGA (1994) Measuring the body composition of elderly subjects: a comparison of methods. Br J Nutr (in press)

  46. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6: 1321–1327

    Google Scholar 

  47. Segal KR, Van Loan M, Fitzgerald PI, Hodgson JA, Van Itallie TB (1988) Lean body mass estimation by bioelectrical impedance analysis: a four site cross validation study. Am J Clin Nutr 47: 7–14

    Google Scholar 

  48. Shils ME, Young VR (1988) Modern nutrition in health and disease. Lea and Febiger, Philadelphia

    Google Scholar 

  49. Shock NW, Watkins DM, Yiengst MJ (1963) Age differences in the water content of the body as related to basal oxygen consumption in males. J Gerontol 18: 1–8

    Google Scholar 

  50. Siri I (1961) Body composition from fluid spaces and density: analysis of methods. In: Brozek J, Herschel A (eds) Techniques for measuring body composition. National Academy of Science, Washington, D. C., pp 223–245

    Google Scholar 

  51. Smith DE, Stevens MCG, Booth IW (1990) Malnutrition in children with malignant solid tumours. J Hum Nutr Diet 3: 303–309

    Google Scholar 

  52. Sulkes A, Collins JM (1987) Reappraisal of some dosage adjustment guidelines. Cancer Treat Rep 71: 229–233

    Google Scholar 

  53. Whiting B, Kelman AW, Grevel J (1986) Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet 11: 387–401

    Google Scholar 

  54. Workman P (1990) The pharmacology of brain tumour chemotherapy. In: Domellof L (ed) Drug delivery in cancer treatment, 3rd edn, ch 11. Springer, Berlin Heidelberg New York, pp 183–200

    Google Scholar 

  55. Workman P, Graham MAL (1993) (eds) Pharmacokinetics in cancer chemotherapy. (Cancer surveys series, vol 17) New York, Cold Spring Harbor Lab. Press

    Google Scholar 

  56. Zimm S, Collins JM, Riccardi R, et al (1983) Variable bioavailability of oral mercaptopurine. N Engl J Med 308: 1005–1009

    Google Scholar 

  57. Zuccaro P, Guandalinis Pacifici R, Pichinis Di Martino L, Guiducci M, Giuliano M, Di Tullio MT, Mantovani MP (1991) Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukaemia. Ther Drug Monit 13: 37–41

    Google Scholar 

Download references

Author information

Author notes

  1. Paul Workman

    Present address: Cancer Research Department, ZENECA Pharmaceuticals, Mereside, SK10 4TG, Alderley Park, Macclesfield, UK

Authors and Affiliations

  1. University of Glasgow Department of Human Nutrition, Yorkhill Hospitals, G3 8SJ, Glasgow, UK

    John J. Reilly

  2. Cancer Research Campaign Beatson Laboratories, CRC Department of Medical Oncology, University of Glasgow, Garscube Estate, G61 1BD, Glasgow, UK

    Paul Workman

Authors
  1. John J. Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Workman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reilly, J.J., Workman, P. Is body composition an important variable in the pharmacokinetics of anticancer drugs?. Cancer Chemother. Pharmacol. 34, 3–13 (1994). https://doi.org/10.1007/BF00686105

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686105

Keywords

Search

Navigation